X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TIL Ltd with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TIL vs INDOCO REMEDIES - Comparison Results

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TIL INDOCO REMEDIES TIL/
INDOCO REMEDIES
 
P/E (TTM) x 23.2 313.6 7.4% View Chart
P/BV x 0.9 2.8 30.9% View Chart
Dividend Yield % 1.4 0.5 277.2%  

Financials

 TIL   INDOCO REMEDIES
EQUITY SHARE DATA
    TIL
Mar-18
INDOCO REMEDIES
Mar-18
TIL/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs686317 216.2%   
Low Rs290178 162.8%   
Sales per share (Unadj.) Rs342.1113.1 302.6%  
Earnings per share (Unadj.) Rs7.64.5 169.2%  
Cash flow per share (Unadj.) Rs19.211.8 162.2%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.70.4 177.6%  
Book value per share (Unadj.) Rs299.273.2 408.5%  
Shares outstanding (eoy) m10.0392.15 10.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.2 65.1%   
Avg P/E ratio x64.655.5 116.5%  
P/CF ratio (eoy) x25.521.0 121.5%  
Price / Book Value ratio x1.63.4 48.2%  
Dividend payout %46.322.4 206.9%   
Avg Mkt Cap Rs m4,89622,830 21.4%   
No. of employees `0001.15.5 20.2%   
Total wages/salary Rs m5812,209 26.3%   
Avg. sales/employee Rs Th3,111.21,910.1 162.9%   
Avg. wages/employee Rs Th527.0405.0 130.1%   
Avg. net profit/employee Rs Th68.775.5 91.1%   
INCOME DATA
Net Sales Rs m3,43210,419 32.9%  
Other income Rs m5547 117.3%   
Total revenues Rs m3,48710,466 33.3%   
Gross profit Rs m3521,349 26.1%  
Depreciation Rs m116677 17.2%   
Interest Rs m178235 75.6%   
Profit before tax Rs m113484 23.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3772 51.7%   
Profit after tax Rs m76412 18.4%  
Gross profit margin %10.312.9 79.3%  
Effective tax rate %33.015.0 220.9%   
Net profit margin %2.24.0 55.9%  
BALANCE SHEET DATA
Current assets Rs m4,2985,373 80.0%   
Current liabilities Rs m3,3764,157 81.2%   
Net working cap to sales %26.911.7 230.2%  
Current ratio x1.31.3 98.5%  
Inventory Days Days26168 385.5%  
Debtors Days Days12973 176.6%  
Net fixed assets Rs m1,3936,244 22.3%   
Share capital Rs m100184 54.4%   
"Free" reserves Rs m2,9016,566 44.2%   
Net worth Rs m3,0016,750 44.5%   
Long term debt Rs m91,233 0.7%   
Total assets Rs m6,43412,363 52.0%  
Interest coverage x1.63.1 53.5%   
Debt to equity ratio x00.2 1.7%  
Sales to assets ratio x0.50.8 63.3%   
Return on assets %3.95.2 75.3%  
Return on equity %2.56.1 41.4%  
Return on capital %9.79.0 107.3%  
Exports to sales %19.60-   
Imports to sales %24.40-   
Exports (fob) Rs m673NA-   
Imports (cif) Rs m837NA-   
Fx inflow Rs m6733,762 17.9%   
Fx outflow Rs m1,0011,143 87.5%   
Net fx Rs m-3282,619 -12.5%   
CASH FLOW
From Operations Rs m-8581,227 -69.9%  
From Investments Rs m30-1,360 -2.2%  
From Financial Activity Rs m862-388 -222.3%  
Net Cashflow Rs m34-521 -6.5%  

Share Holding

Indian Promoters % 37.1 59.2 62.7%  
Foreign collaborators % 19.3 0.0 -  
Indian inst/Mut Fund % 16.0 12.5 128.0%  
FIIs % 2.7 6.0 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.1 22.4 112.1%  
Shareholders   8,301 12,805 64.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TIL With:   COX & KINGS  JSW HOLDINGS  KOTHARI PRODUCTS  S.P. APPARELS  IIFL HOLDINGS  



Today's Market

Sensex Opens in Green; Tata Steel and Axis Bank Top Gainers(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.7% while the Hang Seng is down 0.1%.

Related Views on News

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Garden Reach Shipbuilders and Engineers Ltd: Is This PSU Shipbuilder Worth Betting On? (IPO)

Sep 24, 2018

Should you apply for the IPO of Garden Reach Shipbuilders and Engineers Ltd?

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

The Best Trading Strategy in the World(Profit Hunter)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

L&T: Should Corporates have a Conscience?(The Honest Truth)

Apr 22, 2019

Ajit Dayal believes L&T is taking a risky path and risking not only the culture established at MindTree but the fragile eco system that could endanger the lives of millions of residents in Mumbai.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TIL SHARE PRICE


Apr 26, 2019 11:51 AM

TRACK TIL

COMPARE TIL WITH

MARKET STATS